



# aTyr Pharma

## **aTyr Pharma to Present at the 36th Annual J.P. Morgan Healthcare Conference**

January 4, 2018

SAN DIEGO, Jan. 04, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Sanjay Shukla, M.D., M.S., President and Chief Executive Officer, will present at the 36<sup>th</sup> Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2018 at 8:00 a.m. Pacific Time. The conference will be held at the Westin St. Francis in San Francisco, CA.

Links to a live audio webcast and replay of the presentation may be accessed on the aTyr website events page at: <http://investors.atyrpharma.com/events-and-webcasts>. An audio replay will be available for 90 days following the event.

### **About aTyr Pharma**

aTyr Pharma is engaged in the discovery and development of innovative medicines using its knowledge of newly discovered pathways in immunology effected by extracellular tRNA synthetases. To date, aTyr has generated three innovative and unique development programs based on its knowledge of extracellular histidyl-tRNA synthetase (HARS), known as the Resokine pathway. aTyr's two clinical-stage programs, ATYR1940 (Resolaris) and ATYR1923 (iMod.Fc), are agonists of the Resokine pathway designed to temper immune engagement in diseases characterized by excessive immune cell involvement in muscle and lung. aTyr's third program, ORCA, represents a pre-clinical research program that targets a novel, proprietary immunology pathway using antibodies to enhance the immune response in tumor settings. aTyr has built an intellectual property estate, to protect its pipeline, comprising over 220 issued patents or allowed patent applications that are owned or exclusively licensed, including over 300 potential protein compositions derived from tRNA synthetase genes. For more information, please visit <http://www.atyrpharma.com>.

#### Contact:

Mark Johnson  
Sr. Director, Investor Relations  
[mjohnson@atyrpharma.com](mailto:mjohnson@atyrpharma.com)  
858-223-1163

 [Primary Logo](#)

Source: aTyr Pharma, Inc.